Announcements Trials

Browse Landscape

Status

Active not recruiting 2 Recruiting 1 Not yet recruiting 1 Completed 1 Approved for marketing 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Interventions

Injections 39 Carboplatin 33 Capecitabine 24 Paclitaxel 23 Cisplatin 23 Docetaxel 22 pembrolizumab 21 Oxaliplatin 21 Gemcitabine 21 Bevacizumab 19 Pemetrexed 18 Fluorouracil 13 Irinotecan 12 Cyclophosphamide 11 osimertinib 9 Nivolumab 9 Dexamethasone 8 Topotecan 7 Leucovorin 7 130-nm albumin-bound paclitaxel 7 venetoclax 6 toripalimab 6 tislelizumab 6 regorafenib 6 lenvatinib 6 fludarabine 6 Doxorubicin 6 Cetuximab 6 daratumumab 5 atezolizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × INDUSTRY × vorasidenib × Clear all

NCT06969352 2025-05-13

VICTORIA

Servier (Tianjin) Pharmaceutical Co. LTD.

Not yet recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡